These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2892254)

  • 1. The effect of an oral evening dose of nizatidine on nocturnal and peptone-stimulated gastric acid and gastrin secretion.
    Kovacs TO; Van Deventer GM; Maxwell V; Sytnik B; Walsh JH
    Scand J Gastroenterol Suppl; 1987; 136():41-6. PubMed ID: 2892254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h.
    Lanzon-Miller S; Pounder RE; Chronos NA; Raymond F; Hamilton MR; Dalgleish D
    Gut; 1988 Oct; 29(10):1364-9. PubMed ID: 2904394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.
    Lin TM; Evans DC; Warrick MW; Pioch RP
    J Pharmacol Exp Ther; 1986 Nov; 239(2):406-10. PubMed ID: 2877081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 24-hour acid suppression profile of nizatidine.
    Dammann HG; Gottlieb WR; Walter TA; Müller P; Simon B; Keohane P
    Scand J Gastroenterol Suppl; 1987; 136():56-60. PubMed ID: 2892256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mifentidine on peptone meal-stimulated gastric acid secretion and plasma gastrin levels in duodenal ulcer patients.
    Bianchi Porro G; Imbimbo BP; Lazzaroni M
    Agents Actions; 1988 Aug; 25(1-2):22-6. PubMed ID: 3055874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged inhibition of meal-stimulated acid secretion and gastrin release following single subcutaneous administration of octreotide (SMS 201-995) in man.
    Karnes WE; Maxwell V; Sytnik B; Chew P; Walsh JH
    Aliment Pharmacol Ther; 1989 Dec; 3(6):527-38. PubMed ID: 2518866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhibition of 24-hour acidity by nizatidine].
    Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
    Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of acute stomach ulcer with H2 receptor antagonists. A direct therapy comparison with 300 mg nizatidine nightly and 2 times 150 mg nizatidine with twice daily 150 mg ranitidine].
    Arnold R; Beckenbach P; Bock H; Bormann R; Brunner G; Daake H; Dammann HG; Dietrich K; Fuerer M; Geiter B
    Fortschr Med; 1989 Jun; 107(17):390-4. PubMed ID: 2568327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nizatidine versus ranitidine in the treatment of acute duodenal ulcer. Comparison of 300 mg nizatidine and 300 mg ranitidine in a single evening dose].
    Arnold R; Beckenbach P; Bock H; Bormann R; Daake H; Dammann HG; Du Bosque G; Fürer M; Geiter B; Hebbeln H
    Fortschr Med; 1989 Jul; 107(21):467-70. PubMed ID: 2570012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of 75 mg HOE 760, a novel H2-receptor antagonist, on daytime peptone-stimulated and nocturnal gastric acid output in healthy volunteers.
    Hagenmüller F; Weber C; Hausmann S; Labs R; Malerczyk V; de Looze S; Classen M
    Scand J Gastroenterol; 1987 Jun; 22(5):609-14. PubMed ID: 2888185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of oral nizatidine.
    Vargas R; Ryan J; McMahon FG; Regel G; Offen WW; Matsumoto C
    J Clin Pharmacol; 1988 Jan; 28(1):71-5. PubMed ID: 2895125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
    Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
    Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous nizatidine kinetics and acid suppression.
    Callaghan JT; Bergstrom RF; Obermeyer BD; King EP; Offen WW
    Clin Pharmacol Ther; 1985 Feb; 37(2):162-5. PubMed ID: 2857117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease.
    Thomson AB; Mahachai V; Bailey RJ; Kirdeikis P; Zuk L; Marriage B; Simpson I; Jamali F
    J Gastroenterol Hepatol; 1996 Dec; 11(12):1171-6. PubMed ID: 9034938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.
    Fullarton GM; McLauchlan G; Macdonald A; Crean GP; McColl KE
    Gut; 1989 Apr; 30(4):449-54. PubMed ID: 2565860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine.
    Fullarton GM; Macdonald AM; McColl KE
    Aliment Pharmacol Ther; 1991 Aug; 5(4):391-8. PubMed ID: 1685675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin.
    Hammond JB; Offen WW
    Am J Gastroenterol; 1988 Jan; 83(1):32-6. PubMed ID: 2892392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of various dose regimens of famotidine on basal nocturnal and meal-stimulated gastric secretion.
    Ryan JR; Chremos AN; Vargas R; Mantell G; Johnson CL; McMahon FG
    Clin Pharmacol Ther; 1987 Aug; 42(2):225-31. PubMed ID: 2886245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nizatidine suppression of basal gastric acid output: a comparison of two intravenous dosage regimens.
    Danziger L; Furmaga KM; Rodvold KA; Bombeck CT; Fischer JH
    J Clin Pharmacol; 1989 Oct; 29(10):946-52. PubMed ID: 2574190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of successive doses of nizatidine, cimetidine and ranitidine on serum gastrin level and gastric acid secretion.
    Yamaji Y; Omata T; Abe T; Yoshida A; Ueki S; Aita H; Morita H; Chaki K; Segawa Y; Kurimoto T
    Arzneimittelforschung; 1991 Sep; 41(9):954-7. PubMed ID: 1796924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.